ResMed Inc. (RMD) has seen a series of significant financial moves and evaluations reflected in recent reports. The company's stock has been increased by Pacer Advisors Inc., Swedbank AB and several other entities, while Confluence Investment Management, Thrivent Financial and others have reduced holdings. Goldman Sachs dropped ResMed from its APAC Conviction List, prompting valuation checks, while Baird downgraded to a 'Hold' rating but UBS maintained a 'Buy' rating. ResMed's stock has outperformed the S&P 500, and it is considered a top growth and momentum stock. Numerous expectations forecast ResMed's earnings will grow, backed by beating previous earnings and revenue estimates. The FDA's clearance of the company's AI Smart Comfort CPAP feature may change the bull case for ResMed, and there is also an ongoing U.S. probe into medical device imports. Strategically, ResMed showcases innovation with the launch of a new mask platform and investment in U.S. operations. Notable mentions included ResMed's strong Q3 earnings growth, a declared dividend, strong Q2 sales and accelerator of Q1 revenue growth.
Resmed RMD News Analytics from Thu, 24 Apr 2025 07:00:00 GMT to Sat, 27 Dec 2025 11:33:40 GMT -
Rating 8
- Innovation 7
- Information 8
- Rumor 2
